DBV Technologies (NASDAQ:DBVT) Releases Earnings Results, Misses Estimates By $0.96 EPS

DBV Technologies (NASDAQ:DBVT) issued its quarterly earnings results on Thursday. The company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.96), Zacks reports. The company had revenue of $0.64 million during the quarter, compared to analysts’ expectations of $1.06 million. DBV Technologies had a negative return on equity of 310.56% and a negative net margin of 2,606.83%.

DBV Technologies Stock Performance

DBV Technologies stock opened at $20.00 on Friday. DBV Technologies has a twelve month low of $5.30 and a twelve month high of $26.18. The firm has a market cap of $1.11 billion, a PE ratio of -3.83 and a beta of -0.97. The firm’s 50 day moving average price is $21.58 and its two-hundred day moving average price is $17.22.

Key Stories Impacting DBV Technologies

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

Hedge Funds Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently modified their holdings of the stock. Artisan Partners Limited Partnership grew its stake in DBV Technologies by 6,273.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock valued at $63,435,000 after purchasing an additional 3,257,135 shares in the last quarter. Siren L.L.C. purchased a new stake in shares of DBV Technologies during the 4th quarter worth about $35,606,000. Vivo Capital LLC raised its stake in shares of DBV Technologies by 133.4% during the 4th quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock worth $47,189,000 after purchasing an additional 1,407,120 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of DBV Technologies during the 2nd quarter valued at about $9,659,000. Finally, MPM Bioimpact LLC bought a new stake in shares of DBV Technologies in the 2nd quarter valued at approximately $9,649,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on DBVT shares. HC Wainwright set a $40.00 target price on shares of DBV Technologies in a report on Thursday, December 18th. Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a report on Wednesday, December 17th. Citizens Jmp upped their price target on shares of DBV Technologies from $45.00 to $47.00 and gave the company a “market outperform” rating in a research report on Friday. Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, DBV Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $38.65.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.